Modeling epithelial plasticity-induced erlotinib resistance in non-small cell lung cancer.

被引：0
|
作者：
Wang, Hailun [1 ]
Cades, Jessica [1 ]
Yochum, Zachary [2 ]
Nugent, Katriana [1 ]
Rudin, Charles [3 ]
Burns, Timothy [2 ]
Phuoc Tran [1 ]
机构：
[1] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[2] Univ Pittsburgh, Pittsburgh, PA USA
[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 10期
关键词：
D O I：
10.1158/1538-7445.MOUSEMODELS17-B47
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B47
引用
收藏
页码：77 / 78
页数：2
相关论文
共 50 条
  • [1] Combination of quinacrine and erlotinib overcomes resistance to erlotinib in non-small cell lung cancer
    Dermavvan, Josephine Kam Tai
    Gurova, Katerina
    Pink, John
    Dowlati, Afshin
    De, Sarmishtha
    Naria, Goutham
    Sharma, Neelesh
    Stark, George
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [2] MicroRNA markers for erlotinib resistance in non-small cell lung cancer
    Nelson, Kristen
    Ranade, Aarati
    Kashey, Trevor
    Kingsley, Chris
    Weiss, Glen
    CANCER RESEARCH, 2009, 69
  • [3] Characterising acquired resistance to erlotinib in non-small cell lung cancer patients
    Karachaliou, Niki
    Codony-Servat, Jordi
    Paulina Bracht, Jillian Wilhelmina
    Ito, Masaoki
    Filipska, Martyna
    Pedraz, Carlos
    Chaib, Imane
    Bertran-Alamillo, Jordi
    Felipe Cardona, Andres
    Angel Molina, Miguel
    Rosell, Rafael
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2019, 13 (10) : 1019 - 1028
  • [4] Erlotinib/osimertinibDevelopment of resistance in non-small cell lung cancer: case report
    Reactions Weekly, 2020, 1811 (1) : 123 - 123
  • [5] Identification of microRNAs that promote erlotinib resistance in non-small cell lung cancer
    Pal, A. S.
    Bains, M.
    Agredo, A.
    Kasinski, A. L.
    BIOCHEMICAL PHARMACOLOGY, 2021, 189
  • [6] Erlotinib in non-small cell lung cancer: a review
    Blackhall, FH
    Rehman, S
    Thatcher, N
    EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (06) : 995 - 1002
  • [7] Erlotinib in the treatment of non-small cell lung cancer
    Brown, Ewan R.
    Shepherd, Frances A.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2005, 5 (05) : 767 - 775
  • [8] Preoperative erlotinib in clinical stage I and II non-small cell lung cancer.
    Port, J. L.
    Yankelevitz, D.
    Lee, P. C.
    Spinelli, C.
    Altorki, N. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] Anti-Mullerian hormone regulates epithelial plasticity and survival signaling in non-small cell lung cancer.
    Beck, T. N.
    Korobeynikov, V. A.
    Kudinov, A. E.
    Georgopoulos, R.
    Nicolas, E.
    Einarson, M. B.
    Zhou, Y.
    Boumber, Y.
    Proia, D. A.
    Serebriiskii, I. G.
    Golemis, E. A.
    MOLECULAR BIOLOGY OF THE CELL, 2015, 26
  • [10] Predictors of erlotinib utilization and the impact of erlotinib use on overall survival in advanced, non-small cell lung cancer.
    Ersek, Jennifer L.
    Symanowski, James Thomas
    Kim, Edward S.
    Adams, Swann Arp
    Hebert, James R.
    Eberth, Jan Marie
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345